Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status
Objectives To compare treatment patterns and costs among psoriasis patients with and without metabolic conditions newly initiating a biologic or apremilast. Methods Adult patients included had ≥1 prescription for secukinumab, adalimumab, ustekinumab, etanercept, or apremilast between 01/01/2015 and...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-02-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2019.1698699 |
| _version_ | 1797683607733534720 |
|---|---|
| author | Steven R. Feldman Jingchuan Zhang Diane J. Martinez Lorena Lopez-Gonzalez Elizabeth Hoit Marchlewicz George Shrady Alan M. Mendelsohn Yang Zhao |
| author_facet | Steven R. Feldman Jingchuan Zhang Diane J. Martinez Lorena Lopez-Gonzalez Elizabeth Hoit Marchlewicz George Shrady Alan M. Mendelsohn Yang Zhao |
| author_sort | Steven R. Feldman |
| collection | DOAJ |
| description | Objectives To compare treatment patterns and costs among psoriasis patients with and without metabolic conditions newly initiating a biologic or apremilast. Methods Adult patients included had ≥1 prescription for secukinumab, adalimumab, ustekinumab, etanercept, or apremilast between 01/01/2015 and 08/31/2018 (date of first prescription was index date) and no index drug use in the 12-months pre-index, and continuous enrollment in the 12-month pre-index and 24-month post-index periods. Patients were divided into mutually exclusive treatment cohorts and stratified by their pre-index metabolic condition status. Treatment patterns (adherence, non-persistence, switching, discontinuation, use of combination therapy, and re-initiation) and healthcare costs were compared. Results Overall, 7773 patients were included; 47.5–56.7% had a metabolic condition. Except for the apremilast group, patients with metabolic conditions had higher discontinuation (secukinumab: 50.6% vs. 43.7%; adalimumab*: 53.9% vs. 48.7%; ustekinumab*: 41.9% vs. 35.1%; etanercept: 42.8% vs. 41.2%; apremilast: 43.1% vs. 46.1%) and switching (secukinumab: 48.1% vs. 41.2%; adalimumab*: 47.8% vs. 41.9%; ustekinumab*: 34.5% vs. 25.3%; etanercept*: 53.6% vs. 51.5%; apremilast: 45.8% vs. 44.6%) than patients without (*p < .05). Patients with metabolic conditions incurred significantly higher costs. Conclusion Many psoriasis patients initiating biologics or apremilast had metabolic conditions. These patients had higher discontinuation and switching, and significantly higher healthcare costs. |
| first_indexed | 2024-03-12T00:16:56Z |
| format | Article |
| id | doaj.art-5a8cdfa178a64f2fb35339241871697a |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:16:56Z |
| publishDate | 2021-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-5a8cdfa178a64f2fb35339241871697a2023-09-15T14:23:04ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532021-02-0132220321110.1080/09546634.2019.16986991698699Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition statusSteven R. Feldman0Jingchuan Zhang1Diane J. Martinez2Lorena Lopez-Gonzalez3Elizabeth Hoit Marchlewicz4George Shrady5Alan M. Mendelsohn6Yang Zhao7Wake Forest School of MedicineSun Pharmaceutical IndustriesIBM Watson HealthIBM Watson HealthIBM Watson HealthIBM Watson HealthSun Pharmaceutical IndustriesSun Pharmaceutical IndustriesObjectives To compare treatment patterns and costs among psoriasis patients with and without metabolic conditions newly initiating a biologic or apremilast. Methods Adult patients included had ≥1 prescription for secukinumab, adalimumab, ustekinumab, etanercept, or apremilast between 01/01/2015 and 08/31/2018 (date of first prescription was index date) and no index drug use in the 12-months pre-index, and continuous enrollment in the 12-month pre-index and 24-month post-index periods. Patients were divided into mutually exclusive treatment cohorts and stratified by their pre-index metabolic condition status. Treatment patterns (adherence, non-persistence, switching, discontinuation, use of combination therapy, and re-initiation) and healthcare costs were compared. Results Overall, 7773 patients were included; 47.5–56.7% had a metabolic condition. Except for the apremilast group, patients with metabolic conditions had higher discontinuation (secukinumab: 50.6% vs. 43.7%; adalimumab*: 53.9% vs. 48.7%; ustekinumab*: 41.9% vs. 35.1%; etanercept: 42.8% vs. 41.2%; apremilast: 43.1% vs. 46.1%) and switching (secukinumab: 48.1% vs. 41.2%; adalimumab*: 47.8% vs. 41.9%; ustekinumab*: 34.5% vs. 25.3%; etanercept*: 53.6% vs. 51.5%; apremilast: 45.8% vs. 44.6%) than patients without (*p < .05). Patients with metabolic conditions incurred significantly higher costs. Conclusion Many psoriasis patients initiating biologics or apremilast had metabolic conditions. These patients had higher discontinuation and switching, and significantly higher healthcare costs.http://dx.doi.org/10.1080/09546634.2019.1698699psoriasismetabolic conditionsbiologic therapyapremilast |
| spellingShingle | Steven R. Feldman Jingchuan Zhang Diane J. Martinez Lorena Lopez-Gonzalez Elizabeth Hoit Marchlewicz George Shrady Alan M. Mendelsohn Yang Zhao Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status Journal of Dermatological Treatment psoriasis metabolic conditions biologic therapy apremilast |
| title | Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status |
| title_full | Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status |
| title_fullStr | Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status |
| title_full_unstemmed | Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status |
| title_short | Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status |
| title_sort | real world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate to severe plaque psoriasis by metabolic condition status |
| topic | psoriasis metabolic conditions biologic therapy apremilast |
| url | http://dx.doi.org/10.1080/09546634.2019.1698699 |
| work_keys_str_mv | AT stevenrfeldman realworldtreatmentpatternsandhealthcarecostsofbiologicsandapremilastamongpatientswithmoderatetosevereplaquepsoriasisbymetabolicconditionstatus AT jingchuanzhang realworldtreatmentpatternsandhealthcarecostsofbiologicsandapremilastamongpatientswithmoderatetosevereplaquepsoriasisbymetabolicconditionstatus AT dianejmartinez realworldtreatmentpatternsandhealthcarecostsofbiologicsandapremilastamongpatientswithmoderatetosevereplaquepsoriasisbymetabolicconditionstatus AT lorenalopezgonzalez realworldtreatmentpatternsandhealthcarecostsofbiologicsandapremilastamongpatientswithmoderatetosevereplaquepsoriasisbymetabolicconditionstatus AT elizabethhoitmarchlewicz realworldtreatmentpatternsandhealthcarecostsofbiologicsandapremilastamongpatientswithmoderatetosevereplaquepsoriasisbymetabolicconditionstatus AT georgeshrady realworldtreatmentpatternsandhealthcarecostsofbiologicsandapremilastamongpatientswithmoderatetosevereplaquepsoriasisbymetabolicconditionstatus AT alanmmendelsohn realworldtreatmentpatternsandhealthcarecostsofbiologicsandapremilastamongpatientswithmoderatetosevereplaquepsoriasisbymetabolicconditionstatus AT yangzhao realworldtreatmentpatternsandhealthcarecostsofbiologicsandapremilastamongpatientswithmoderatetosevereplaquepsoriasisbymetabolicconditionstatus |